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TO THE EDITOR
Melanoma is a highly metastatic and
therapeutically resistant cancer whose
incidence has more than tripled in the
past decades (Smalley et al., 2008).
Physiologically, melanocytes produce
and store melanin pigments in the
melanosomes, which are transported
to the cell periphery and transferred
to keratinocytes, a process that requires
the tripartite complex Rab27a/
melanophilin/myosin-Va (Hume and
Seabra, 2011). Myosin-Va is an
actin-based molecular motor that also
serves a multitude of other functions,
such as plasma membrane receptor
recycling; exocytosis; association with
nuclear speckles and the centrosome
(see Woolner and Bement, 2009); inte-
raction with phosphatase and tensin
homolog, thereby modulating the phos-
phoinositide 3-kinase pathway (van
Diepen et al., 2009); interaction with
Bcl-xL, proposed to promote invasion of
islet-tumor cells (Du et al., 2007); and as
a biomarker of invasiveness for nonfunc-
tioning pituitary adenomas (Galland
et al., 2010). Moreover, myosin-Va was
shown to be upregulated by Snail to
promote cancer cell invasion (Lan et al.,
2010), and was postulated to control
apoptosis by sequestering the pro-
apoptotic protein Bmf, which is
unleashed upon loss of cell attachment
(Puthalakath et al., 2001).
Upregulation of MYO5A gene in
melanoma and other cancer types was
revealed in different microarray studies
compiled here (Supplementary Table S1
online and Supplementary Figure S1
online). However, these data did not
clarify whether MYO5A upregulation
was associated with melanocyte trans-
formation or simply reflected tissue
specificity, as comparison was against
normal skin and melanocytes are minor
cells in the skin. Here we extended this
evidence by showing that MYO5A is
upregulated in a variety of melanoma
cell lines in comparison with primary
melanocytes (Figure 1a), as well as in
metastatic cells in comparison with
paired vertical growth phase cells
(Figure 1b and Supplementary Figure
S2 online), implicating myosin-Va in
malignant transformation and/or mela-
noma progression. Interestingly, in this
WM panel, myosin-Va expression
correlated with that of the oncogenic
transcription factor MITF (Sousa and
Espreafico, 2008).
To investigate the role of myosin-Va
in melanoma cells, we knocked down
this protein using three different short
hairpin RNAs (shMYO5A#1–3) carried
by lentiviral vectors (Supplementary
Figure S3 online and Qin et al., 2003)
and a small interfering RNA (siMYO5A).
Once efficient knockdown was attained
(Figure 1c–e), functional studies were
conducted. Upon adhesion to fibronectin-
coated glass coverslips, MYO5A-depleted
cells showed numerous small blebs on
their surface and reduced lamellipodia/
filopodia formation (Figure 1f), besides
deficient adhesion (Figure 1g) and
spreading (Figure 1h).
Next, we examined the role of myo-
sin-Va in adhesion-independent growth.
The ability to form colony in soft agar,
as analyzed after 25–30 days of incuba-
tion, was at least 50% lower for
MYO5A-depleted cells than controls,
for the three different short hairpin RNAs
used (Figure 2a). Proliferation rates
under adherent conditions were deter-
mined by crystal violet staining for
WM1617 (Figure 2b) or ATP measure-
ments for UACC-257 (Figure 2f),
and no differences were observed, in
the time courses analyzed, between
MYO5A knockdown and control cells.
Subsequently, we analyzed transwell
migration and invasion and found rates
50–70% lower for shMYO5A#2/3-
transfected WM1617 cells than
controls (Figure 2c). Similar decrease in
transwell invasion was observed for
siMYO5A-transfected UACC-257 cells
(Figure 2e). Next, we performed
spheroid assays (as in Smalley et al.,
2008) with shMYO5A#1-transduced
cells. Compact spheroids with intact
appearance were added to a tridimen-
sional collagen gel and imaged after 24
and 48 hours of culture. Myosin-Va-
depleted cells exhibited migration
distances from the spheroid margin to
the invasion front 50–60% shorter
than controls (Figure 2d). In addition,
knockdown cells that migrated out of
the spheroids looked smaller than con-
trols after 48 hours, suggesting that
myosin-Va-depleted cells differ in the
sensitivity to microenvironment factors
during migration in collagen matrix.
The multifunctional character of
myosin-Va makes us believe that this
molecular motor, in addition to its role
in cell adhesion/motility by promoting
focal adhesion dynamics and filopodia/
lamillipodia growth (supported by work
in progress from our group), may also
perform a role in extracellular matrix
proteolysis, mediating surface exposure
and positioning of matrix metalloprotei-
nases. Indeed, the alignment of metallo-
proteinases along the cytoskeleton
seems to be a prerequisite for cell
invasion in melanoma. In addition,
colocalization of metalloproteinases
with myosin-Va (Sbai et al., 2010) in
astrocytes and a role for RAB27A
(Bobrie et al., 2012) in the release of
metalloproteinase-9 to promote meta-
stasis of mammary carcinoma cells
have been shown. Moreover, evidence
that RAB27A (Akavia et al., 2010)
functions as a driver of cancer
supports the hypothesis that, similarly,
myosin-Va promotes malignancy by
functioning in vesicular trafficking.
Indeed, endocytosis and recycling ofAccepted article preview online 7 May 2013; published online 11 July 2013
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plasma membrane receptors require Rab
GTPases and molecular motors with
reflexes in adhesion dynamics, cell
signaling, and metabolism in many
instances shown to drive oncogenic
transformation and invasion (Mosesson
et al., 2008). Furthermore, the relevance
of our findings is supported by recent
report demonstrating that the formation
of filopodia is a critical step in the
metastasis cascade (Shibue et al., 2012).
In addition, we cannot rule out the
possibility that some of the effects
observed could be due to an increase
in the rates of apoptosis in the MYO5A
knockdown cells. Although we have not
observed alteration of viability after
myosin-Va depletion in short-term cul-
turing under regular conditions, increase
of apoptosis rates under adhesion block-
age and poor recovery of frozen stocks
were noted. In fact, recent independent
findings reinforce participation of
myosin-Va in the control of apoptosis.
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Figure 1. Myosin-Va is highly expressed in melanoma cells, and its knockdown impairs cell adhesion and spreading on the fibronectin-coated surface.
(a) Relative MYO5A mRNA expression detected by quantitative PCR in melanocytes (pMel1 to 4) versus melanoma cells, using b-actin for normalization and mean
of all melanocytes as reference value. (b) Western blot of myosin-Va in a panel of melanoma cell lines of radial growth phase (RGP), vertical growth phase (VGP),
and metastasis (M), including two genetic pairs (WM793 and 1205Lu; WM278 and WM1617). (c–e) Western blots for myosin-Va in (c, d) WM1617 and
(e) UACC-257. WM1617 cells were lysed 3 days after transduction with lentiviral vectors carrying short hairpin RNAs (shRNAs) targeted to bacterial Lac-Z
(shControl) or MYO5A (shMYO5A#1), or after stable selection with antibiotics for about 2–3 weeks in the case of shMYO5A#2–3 and respective shControl
(Supplementary Figure S3). UACC-257 cells were lysed 3 days after transfection with small interfering RNA against myosin-Va (siMYO5A, obtained from
Dharmacon SmartPool, LQ-019321-00-0002) or control (siControl, Dharmacon On-Target Non-Targeting Pool, D-001810-10). (f) Confocal images of F-actin-
stained cells adhered to fibronectin-coated coverslips for the indicated times. Arrows indicate transduced cells visualized by green fluorescent protein expression
(inserts). Bar ¼ 20mm. (g) Cells allowed to adhere on fibronectin-coated surface for the indicated times were counted and data were plotted as mean±SD from
three independent experiments (*Po0.005). (h) Cell spreading. Imaged as in f, and the areas for 60 cells/time point were measured using ImageJ (*Po0.001).
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Bmf sequestration to the actin cytoske-
leton, presumably in complex with
myosin-Va/DLC2, promotes resistance
to MEK inhibitors (van Brocklin et al.,
2009). Accordingly, overexpression of
myosin-Va tail fragments harboring the
binding site for DLC2 leads to apoptosis
in melanoma cells probably by
disrupting Bmf and also Bim anchorage
(Izidoro-Toledo et al., 2013). Finally,
miR-145, which is a transcriptional
target of p53 and known to act as a
tumor suppressor, was recently shown
to target myosin-Va (Dynoodt et al.,
2013). Therefore, myosin-Va may
integrate mechanisms that interconnect
invasion/migration machinery and resi-
stance to apoptosis. Interdependencies
between these processes are reviewed
in Alexander and Friedl (2012).
In summary, the data presented
here show that myosin-Va promo-
tes adhesion dynamics, anchorage-
independent survival, migration, and
invasion in vitro. Therefore, upregula-
tion of myosin-Va during melanoma
progression may be part of a general
mechanism that promotes malignant
properties.
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Figure 2. Ablation of myosin-Va inhibits colony formation, migration, and invasiveness of metastatic melanoma cells without affecting cell proliferation. (a–c)
Lentiviral-transduced WM1617 cells, using three independent shMYO5A or shControls, were used to assess the following: (a) colony formation in soft agar after 30
days of growth, bar ¼ 500mm; (b) proliferation rates by absorbance measurement of crystal violet staining; (c) migration in transwell and invasion in the transwell-
matrigel assay. Cells were kept in starvation conditions 24 hour before the assay and were then allowed to migrate/invade for 24 hours. Bar ¼ 50mm. (d) Migration
in three-dimensional collagen. After 24 or 48 hours of incubation, distance from the spheroid edge to the invasive front was measured and the data from three
independent experiments were plotted as a percentage of control. Bar ¼ 100mm. (e and f) Transwell invasion and proliferation rates of UACC-257 cells transiently
transfected with duplex small interfering RNA (siRNA) targeted to MYO5A and irrelevant siRNA. Invasion assay was performed as described in c, and proliferation
rates were estimated based on ATP measurements. Data were plotted as mean±SD from three independent experiments. Bar ¼ 50mm.
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SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
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